These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 24289103)
1. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103 [TBL] [Abstract][Full Text] [Related]
2. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Ignatov A; Ignatov T; Roessner A; Costa SD; Kalinski T Breast Cancer Res Treat; 2010 Aug; 123(1):87-96. PubMed ID: 19911269 [TBL] [Abstract][Full Text] [Related]
3. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells. Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368 [TBL] [Abstract][Full Text] [Related]
5. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Girgert R; Emons G; Gründker C Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080 [TBL] [Abstract][Full Text] [Related]
6. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells]. Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274 [TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Fan P; Wang J; Santen RJ; Yue W Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173 [TBL] [Abstract][Full Text] [Related]
8. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159 [TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related]
10. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451 [TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302 [TBL] [Abstract][Full Text] [Related]
12. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023 [TBL] [Abstract][Full Text] [Related]
13. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826 [TBL] [Abstract][Full Text] [Related]
14. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Ignatov A; Ignatov T; Weissenborn C; Eggemann H; Bischoff J; Semczuk A; Roessner A; Costa SD; Kalinski T Breast Cancer Res Treat; 2011 Jul; 128(2):457-66. PubMed ID: 21607586 [TBL] [Abstract][Full Text] [Related]
15. New approaches to the understanding of tamoxifen action and resistance. Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788 [TBL] [Abstract][Full Text] [Related]
16. GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts. Luo H; Yang G; Yu T; Luo S; Wu C; Sun Y; Liu M; Tu G Endocr Relat Cancer; 2014 Apr; 21(2):355-69. PubMed ID: 24481325 [TBL] [Abstract][Full Text] [Related]
17. Activation of GPR30 with G1 attenuates neuronal apoptosis via src/EGFR/stat3 signaling pathway after subarachnoid hemorrhage in male rats. Peng J; Zuo Y; Huang L; Okada T; Liu S; Zuo G; Zhang G; Tang J; Xia Y; Zhang JH Exp Neurol; 2019 Oct; 320():113008. PubMed ID: 31295444 [TBL] [Abstract][Full Text] [Related]
18. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Filardo EJ; Quinn JA; Frackelton AR; Bland KI Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440 [TBL] [Abstract][Full Text] [Related]
19. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]